Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study.

Autor: Ume L Abbas, Robert L Glaubius, Yajun Ding, Gregory Hood

Publikováno v: PLoS ONE, Vol 14, Iss 7, p e0218649 (2019)

BACKGROUND:Tenofovir-containing regimens comprise the preferred first-line antiretroviral therapy (ART) in many countries including South Africa, where utilization of second-line regimens is limited. Considerable HIV drug resistance has occurred amon

Externí odkaz: https://doaj.org/article/c448515d1b694f10b29b41474911f8a7

Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings.

Autor: Ume L Abbas, Roy M Anderson, John W Mellors

Publikováno v: PLoS ONE, Vol 2, Iss 9, p e875 (2007)

BackgroundThe potential impact of pre-exposure chemoprophylaxis (PrEP) on heterosexual transmission of HIV-1 infection in resource-limited settings is uncertain.Methodology/principle findingsA deterministic mathematical model was used to simulate the

Externí odkaz: https://doaj.org/article/f58f80ef2d364825a87a47e4337a9157

Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa: a comparison of mathematical models

Autor: David A. M. C. van de Vijver, Brooke E Nichols, Charles A. Boucher, Timothy B. Hallett, Katrina A. Lythgoe, Ume L. Abbas, Jeffrey W. Eaton, John W. Mellors, Kim C. E. Sigaloff, Andrew N. Phillips, Robert Glaubius, Valentina Cambiano

Publikováno v: AIDS, 27(18), 2943-2951. Lippincott Williams and Wilkins
AIDS (London, England), 27(18), 2943-2951. Lippincott Williams and Wilkins
AIDS, 27(18), 2943-2951. Lippincott Williams & Wilkins
Vijver, D A M C V D, Nichols, B E, Abbas, U L, Boucher, C A B, Cambiano, V, Eaton, J W, Glaubius, R, Lythgoe, K, Mellors, J, Phillips, A, Sigaloff, K C & Hallett, T B 2013, ' Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa : A comparison of mathematical models ', AIDS, vol. 27, no. 18, pp. 2943-2951 . https://doi.org/10.1097/01.aids.0000433237.63560.20

Background: Preexposure prophylaxis (PrEP) with tenofovir and emtricitabine can prevent new HIV-1 infections, but there is a concern that use of PrEP could increase HIV drug resistance resulting in loss of treatment options. We compared standardized

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7eebc7ea75255cea867964bc53e9e8d
https://ora.ox.ac.uk/objects/uuid:9cca44c0-f0e3-48ea-ab2b-627459e72956

Clinical spectrum of COVID-19 and plasma angiotensin II levels

Autor: Mayar Al Mohajer, Todd M. Lasco, Gustavo A. Rivero, Sidra Younus, Shital M. Patel, An-Lin Cheng, Ume L. Abbas

Publikováno v: Current Topics in Virology. 18:25

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::03d5a02533942e3998a5dbc5c9a62861
https://doi.org/10.31300/ctvr.18.2021.25-30

Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study

Autor: Gregory Hood, Ume L. Abbas, Robert Glaubius, Yajun Ding

Publikováno v: PLoS ONE
PLoS ONE, Vol 14, Iss 7, p e0218649 (2019)

Background Tenofovir-containing regimens comprise the preferred first-line antiretroviral therapy (ART) in many countries including South Africa, where utilization of second-line regimens is limited. Considerable HIV drug resistance has occurred amon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5bfd0de50a96d02f2890d67af6ef0e
https://pubmed.ncbi.nlm.nih.gov/31269034